PDX model details
| PDX ID |
435.1A Cx |
| Host Strain(and Source) |
NSG Source: Monash University |
| Host Strain Immune system Humanized |
NO |
| Host Type |
Castrate |
| Graft Site |
Subcutaneous |
Current Generation (* indicates number of generations grown in Castrate host) |
17 (13*) |
| Average PDX Generation Time (days +/- SEM) |
56 ± 2 |
| Tumour preparation |
Tumor solid |
| Tumour Characterization Technology |
Histology, IHC, STR profiling, targeted DNA sequencing, RNAseq |
| Tumour confirmed not to be of Mouse/EBV origin |
Yes; negative for CD45 and/or positive for human CK8/18 and/or human mitochondria by IHC |
| Passage QA performed |
Routine QA every 2-3 passages |
| Associated meta data |
| PDX model availability |
Yes (fixed, frozen or cryopreserved tissue) |
| Governance restriction for distribution |
Available to investigators with appropriate ethics approvals, approved EOI from MURAL committee, and material transfer agreements |
| Pubmed ID |
34413304 |
| |
|
| Markers |
435.1A Cx |
| AR |
N |
| PSA |
N |
| PSMA |
N |
| NE |
Y |
| ERG |
N |
This heatmap displays the call type of curated CNVs in the presented samples.
This heatmap displays the call type of CNVs in commonly occurred samples.
This table displays curated CNVs
|
PDX ID
|
Gene Symbol
|
CNV Log2
|
CNV Copy
|
CNV Call
|
Experiments name
|
Platform
|
Reference genome
|
| 435.1A Cx |
USP28 |
-1.027 |
0.982 |
Loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 435.1A Cx |
TP53 |
-28.584 |
4.970e-09 |
Homdel
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 435.1A Cx |
ZNRF3 |
-1.004 |
0.997 |
Loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 435.1A Cx |
ZNRF3 |
-1.228 |
0.854 |
Loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 435.1A Cx |
FANCA |
-1.266 |
0.831 |
Loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 435.1A Cx |
FANCA |
-1.097 |
0.935 |
Loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 435.1A Cx |
ZFHX3 |
-0.959 |
1.029 |
Loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 435.1A Cx |
ZFHX3 |
-0.822 |
1.131 |
Loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 435.1A Cx |
CDH1 |
-1.209 |
0.865 |
Loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 435.1A Cx |
MGA |
-1.045 |
0.970 |
Loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 435.1A Cx |
RB1 |
-1.328 |
0.797 |
Loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 435.1A Cx |
BRCA2 |
-0.961 |
1.028 |
Loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 435.1A Cx |
PIK3CB |
1.182 |
4.537 |
Gain
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 435.1A Cx |
SUFU |
-0.979 |
1.015 |
Loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 435.1A Cx |
APC |
-0.953 |
1.033 |
Loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 435.1A Cx |
CHD1 |
-0.953 |
1.033 |
Loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 435.1A Cx |
SMARCAD1 |
-0.843 |
1.115 |
Loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 435.1A Cx |
CUL3 |
-1.085 |
0.943 |
Loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 435.1A Cx |
CUL3 |
-0.881 |
1.086 |
Loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 435.1A Cx |
ERBB4 |
-0.881 |
1.086 |
Loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 435.1A Cx |
IGF2R |
0.600 |
3.031 |
Gain
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 435.1A Cx |
GEMIN5 |
0.547 |
2.922 |
Gain
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 435.1A Cx |
TCERG1 |
0.612 |
3.056 |
Gain
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
Clinical Information
| Sample Number |
435.1A |
| Sample Site |
Right temporal fossa |
| Sample source |
Autopsy |
| Pathology Tumour Diagnosis |
None |
| Gleason Score |
None |
| Primary Gleason Score |
None |
| Secondary Gleason Score |
None |
| Tertiary Gleason Score |
None |
| ISUP Grade Group |
|
| Tumour Grade |
|
| D'Amico Risk Classification |
|
| Tumour Volume (in cc) |
0.0 |
| Treatment Prior to Specimen Collection |
ADT, carboplatin plus etoposide |
| |
|
Patient Information
| Patient Number |
435 |
| Sex |
Male |
| Diagnosis |
Prostate Cancer |
| PSA at diagnosis (ng/mL) |
16.2 |
| Consent to share data |
|
| |
|
This heatmap displays the mutations of curated sequence variants.
Download Plot
This table displays curated sequence variants
|
PDX ID
|
Gene Symbol
|
Total Read Depth
|
Alternate Frequency
|
Consequence
|
Exon
|
GnomAD AF
|
CADD PHRED score
|
ClinVar significance
|
Platform
|
Experiments Name
|
Reference
|
Library Type
|
Instrument Type
|
| 435.1A Cx |
ZFHX3 |
277 |
1.0 |
Missense variant |
'4/10 |
1.63E-05 |
32 |
-
|
Targeted Twist Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
NextSeq 500 |
| 435.1A Cx |
BRCA2 |
216 |
1.0 |
Frameshift variant |
'11/28 |
. |
. |
-
|
Targeted Twist Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
NextSeq 500 |
| 435.1A Cx |
SUPV3L1 |
590 |
0.65 |
Missense variant |
'13/15 |
. |
31 |
-
|
Targeted Twist Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
NextSeq 500 |
| 435.1A Cx |
PRKDC |
294 |
0.51 |
Missense variant |
'1/87 |
. |
24.9 |
-
|
Targeted Twist Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
NextSeq 500 |
| 435.1A Cx |
TSHR |
492 |
0.49 |
Missense variant |
'11/11 |
. |
27.2 |
-
|
Targeted Twist Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
NextSeq 500 |
| 435.1A Cx |
NTRK2 |
397 |
0.49 |
Missense variant |
'10/21 |
. |
27.3 |
-
|
Targeted Twist Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
NextSeq 500 |
| 435.1A Cx |
NOTCH3 |
402 |
0.44 |
Missense variant |
'33/33 |
1.28E-05 |
28.5 |
-
|
Targeted Twist Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
NextSeq 500 |
| 435.1A Cx |
IRF4 |
419 |
0.44 |
Missense variant |
'3/9 |
3.66E-05 |
21.5 |
-
|
Targeted Twist Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
NextSeq 500 |
| 435.1A Cx |
NOTCH2 |
490 |
0.41 |
Frameshift variant |
'34/34 |
. |
. |
-
|
Targeted Twist Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
NextSeq 500 |
| 435.1A Cx |
ATAD2B |
443 |
0.33 |
Missense variant |
'1/28 |
. |
25.1 |
-
|
Targeted Twist Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
NextSeq 500 |
No information in Gene expression
No information in Drug dosing Table